Current evidence
Textbook questions recently corrected against current guidelines and sources, plus the physician-approved questions of the featured Updates articles, so that new knowledge enters your study flow.
Questions updated against a source
Questions from the Updates articles
Does the tumour absorbed dose predict survival with Lu-177 DOTATATE?
Test yourself
In the ILUMINET analysis by Warfvinge et al. (J Nucl Med 2026), how was each patient's tumour dose summarised?
In the same study, which is true for patients in the top quartile of cumulative tumour dose (>118 Gy)?
In the ILUMINET trial, what determined the number of [177Lu]Lu-DOTATATE cycles?
Total tumour volume on PSMA PET: predicting survival with a single number
Test yourself
In the PROMISE registry analysis by Karpinski et al. (J Nucl Med 2026), which metric had the lowest C-index in the validation cohort?
In the same study, which group had a median overall survival of 4.4 years?
Under RECIP 1.0, what defines partial response on interim PET during Lu-177 PSMA therapy?
Does giving Lu-177 DOTATATE through the hepatic artery make a difference in liver metastases?
Test yourself
What was the primary endpoint of the LUTIA trial, and what was the result?
What principle underlies giving the radiopeptide into the hepatic artery?
When interpreting the more than threefold dose difference in Bodei et al. (J Nucl Med 2026), what should be kept in mind?